Infinity Pharmaceuticals | INFI - Interest Expense On Debt


Infinity Pharmaceuticals reported $45K in Interest Expense on Debt for its fiscal quarter ending in June of 2023.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Cipla INR 131.3M 9M Mar/2026
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Eisai JPY 1.55B 117M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Grifols EUR 156.07M 31.46M Sep/2025
Incyte USD 569K 13K Mar/2026
Infinity Pharmaceuticals USD 45K 0 Jun/2023
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
J&J USD 43M 25M Mar/2026
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
Plus Therapeutics USD 62K 25K Dec/2023
Roche Holding CHF 304M 7.5M Jun/2025
TG Therapeutics USD 7.67M 1.13M Mar/2026